Which hedge funds own AMPH? AMPHASTAR PHARMACEUTICALS IN, Q2 2026 13F holders
22 tracked hedge funds disclosed a position in AMPH (AMPHASTAR PHARMACEUTICALS IN) in their Q2 2026 13F filings, worth $69.8m in total. The largest holder by portfolio weight is Corient IA LP at 0.1% of its book. 8 opened a new position this quarter: Fox Run Management, L.L.C., Campbell & CO Investment Adviser LLC, Y-Intercept (Hong Kong) Ltd, Engineers Gate Manager LP. 5 exited: Quantedge Capital Pte Ltd, PDT Partners, LLC, Trexquant Investment LP.
- 22
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 8
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 5
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $3.5m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $2.4m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $69.8m
- Combined value Sum of the holders' reported positions in the security.
- 1.8%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Quantedge Capital Pte Ltd | 0.1% | $264k |
| PDT Partners, LLC | 0.01% | $224k |
| Trexquant Investment LP | 0.01% | $938k |
| Freestone Grove Partners LP | 0.0% | $585k |
| Verition Fund Management LLC | 0.0% | $364k |
Ownership over time
Who discovered AMPH first? Beta
| Quantedge Capital Pte Ltd | Q2 2022 | −0.5 pts |
| Boone Capital Management LLC high conviction | Q4 2023 | −1.1 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.